Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Accumulated Expenses: 2012-2024

Historic Other Accumulated Expenses for Cytokinetics (CYTK) over the last 13 years, with Dec 2024 value amounting to $9.8 million.

  • Cytokinetics' Other Accumulated Expenses rose 12.63% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 12.63%. This contributed to the annual value of $9.8 million for FY2024, which is 7.06% down from last year.
  • According to the latest figures from FY2024, Cytokinetics' Other Accumulated Expenses is $9.8 million, which was down 7.06% from $10.6 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Other Accumulated Expenses peaked at $10.6 million during FY2023, and registered a low of $1.4 million during FY2020.
  • Its 3-year average for Other Accumulated Expenses is $8.9 million, with a median of $9.8 million in 2024.
  • In the last 5 years, Cytokinetics' Other Accumulated Expenses declined by 10.29% in 2020 and then surged by 296.58% in 2021.
  • Yearly analysis of 5 years shows Cytokinetics' Other Accumulated Expenses stood at $1.4 million in 2020, then surged by 296.58% to $5.6 million in 2021, then rose by 11.78% to $6.2 million in 2022, then surged by 69.65% to $10.6 million in 2023, then declined by 7.06% to $9.8 million in 2024.